Retifanlimab Clinical Trials
15 recruitingDrug
Phase 19Phase 29Phase 31Early Phase 11
Showing 1–15 of 15 trials
Recruiting
Phase 1Phase 2
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Metastatic Colorectal Cancer
National Cancer Institute (NCI)60 enrolled1 locationNCT06149481
Recruiting
Phase 1Phase 2
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Soft Tissue SarcomaSarcomaSarcoma,Soft Tissue+1 more
Memorial Sloan Kettering Cancer Center98 enrolled1 locationNCT04577014
Recruiting
Early Phase 1
A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma
BRAF V600E Mutation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins24 enrolled1 locationNCT06610682
Recruiting
Phase 3
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Breast CancerBreast Cancer MetastaticMetastatic Breast Cancer+2 more
BriaCell Therapeutics Corporation404 enrolled79 locationsNCT06072612
Recruiting
Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Solid Tumors
Incyte Corporation710 enrolled34 locationsNCT06179160
Recruiting
Phase 2
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
GliomaOligodendrogliomaAstrocytoma+1 more
Stephen Bagley, MD, MSCE55 enrolled1 locationNCT05345002
Recruiting
Phase 1Phase 2
Retifanlimab and Ruxolitinib In Solid Malignancies
University of California, San Diego40 enrolled1 locationNCT07219576
Recruiting
Phase 1
Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins50 enrolled1 locationNCT05083754
Recruiting
Phase 1Phase 2
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
Metastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm+1 more
OHSU Knight Cancer Institute38 enrolled1 locationNCT06320405
Recruiting
Phase 1Phase 2
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
University of Washington35 enrolled1 locationNCT05455697
Recruiting
Phase 1
A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
Breast Cancer
M.D. Anderson Cancer Center24 enrolled1 locationNCT06959537
Recruiting
Phase 1
9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
Pancreatic Adenocarcinoma
Anwaar Saeed12 enrolled1 locationNCT06896188
Recruiting
Phase 2
A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
Dedifferentiated Liposarcoma
Lund University Hospital33 enrolled4 locationsNCT06389799
Recruiting
Phase 2
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Recurrent GlioblastomaRecurrent WHO Grade 4 Glioma
Academic and Community Cancer Research United134 enrolled3 locationsNCT06160206
Recruiting
Phase 2
Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)
Esophageal AdenocarcinomaGastric Adenocarcinoma
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)25 enrolled8 locationsNCT05177133